Sienna Biopharmaceuticals Stock Price, News & Analysis (NASDAQ:SNNA)

$19.03 -0.20 (-1.04 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$19.23
Today's Range$18.95 - $19.37
52-Week Range$15.22 - $29.25
Volume24,572 shs
Average Volume72,209 shs
Market Capitalization$390.86 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Sienna Biopharmaceuticals (NASDAQ:SNNA)

Sienna Biopharmaceuticals logoSienna Biopharmaceuticals, Inc. is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125. The Company has developed over 70 products. Its SNA-120 and SNA-125 are generated through its Topical by Design platform technology. Its SNA-120 is a Topical Tropomyosin Receptor Kinase A (TrkA) inhibitor for pruritus and psoriasis. Its SNA-125 is a Topical TrkA/Janus Kinase 3 (JAK3) Inhibitor for atopic dermatitis, psoriasis and pruritus. Its SNA-001 is a Topical Photoparticle Therapy for medical and aesthetic applications. Its SNA-001 Topical Photoparticle Therapy is used for localized and non-systemic treatment of acne. Its SNA-001 Topical Photoparticle Therapy is used for reduction of light-pigmented hair.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:SNNA
  • CUSIP: N/A
  • Web: siennabio.com
Debt:
  • Current Ratio: 6.72%
  • Quick Ratio: 6.72%
Misc:
  • Employees: 43
  • Outstanding Shares: 20,540,000
 

Frequently Asked Questions for Sienna Biopharmaceuticals (NASDAQ:SNNA)

What is Sienna Biopharmaceuticals' stock symbol?

Sienna Biopharmaceuticals trades on the NASDAQ under the ticker symbol "SNNA."

How were Sienna Biopharmaceuticals' earnings last quarter?

Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) issued its earnings results on Thursday, September, 7th. The company reported ($6.50) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $5.82. View Sienna Biopharmaceuticals' Earnings History.

When will Sienna Biopharmaceuticals make its next earnings announcement?

Sienna Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, December, 7th 2017. View Earnings Estimates for Sienna Biopharmaceuticals.

Where is Sienna Biopharmaceuticals' stock going? Where will Sienna Biopharmaceuticals' stock price be in 2017?

3 brokers have issued 1-year target prices for Sienna Biopharmaceuticals' stock. Their predictions range from $28.00 to $50.00. On average, they expect Sienna Biopharmaceuticals' share price to reach $36.00 in the next twelve months. View Analyst Ratings for Sienna Biopharmaceuticals.

Who are some of Sienna Biopharmaceuticals' key competitors?

Who are Sienna Biopharmaceuticals' key executives?

Sienna Biopharmaceuticals' management team includes the folowing people:

  • Frederick C. Beddingfield III, M.D., Ph.D., President, Chief Executive Officer, Director (Age 51)
  • Richard D. Peterson, Chief Financial Officer (Age 49)
  • Majed Kheir, Vice President - Operations
  • Susan Lundeen, Vice President - Human Resources
  • Robert More, Director

When did Sienna Biopharmaceuticals IPO?

(SNNA) raised $64 million in an initial public offering (IPO) on Thursday, July 27th 2017. The company issued 4,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets acted as the underwriters for the IPO.

Who owns Sienna Biopharmaceuticals stock?

Sienna Biopharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (2.23%), TimesSquare Capital Management LLC (1.88%), Alyeska Investment Group L.P. (0.25%), Citadel Advisors LLC (0.10%), Bank of New York Mellon Corp (0.06%) and California State Teachers Retirement System (0.04%). Company insiders that own Sienna Biopharmaceuticals stock include Dennis M Fenton, Keith R Leonard, Paul F Lizzul, Richard D Peterson and Timothy K Andrews. View Institutional Ownership Trends for Sienna Biopharmaceuticals.

Who bought Sienna Biopharmaceuticals stock? Who is buying Sienna Biopharmaceuticals stock?

Sienna Biopharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., TimesSquare Capital Management LLC, Alyeska Investment Group L.P., Citadel Advisors LLC, Bank of New York Mellon Corp and California State Teachers Retirement System. Company insiders that have bought Sienna Biopharmaceuticals stock in the last two years include Dennis M Fenton, Keith R Leonard, Paul F Lizzul, Richard D Peterson and Timothy K Andrews. View Insider Buying and Selling for Sienna Biopharmaceuticals.

How do I buy Sienna Biopharmaceuticals stock?

Shares of Sienna Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sienna Biopharmaceuticals' stock price today?

One share of Sienna Biopharmaceuticals stock can currently be purchased for approximately $19.03.

How big of a company is Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals has a market capitalization of $390.86 million. Sienna Biopharmaceuticals employs 43 workers across the globe.

How can I contact Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Rd Ste 140, WESTLAKE VILLAGE, CA 91362-7327, United States. The company can be reached via phone at +1-818-6292256 or via email at [email protected]


MarketBeat Community Rating for Sienna Biopharmaceuticals (NASDAQ SNNA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  85
MarketBeat's community ratings are surveys of what our community members think about Sienna Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Sienna Biopharmaceuticals (NASDAQ:SNNA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $36.00 (89.17% upside)

Consensus Price Target History for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Price Target History for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Analysts' Ratings History for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/21/2017Cowen and CompanyInitiated CoverageOutperform$50.00HighView Rating Details
8/21/2017J P Morgan Chase & CoInitiated CoverageOverweight -> Overweight$28.00HighView Rating Details
8/21/2017BMO Capital MarketsInitiated CoverageOutperform$30.00HighView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Earnings by Quarter for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Earnings History by Quarter for Sienna Biopharmaceuticals (NASDAQ SNNA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/7/2017        
9/7/2017Q2 2017($0.68)($6.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sienna Biopharmaceuticals (NASDAQ:SNNA)
Current Year EPS Consensus Estimate: $-2.1 EPS
Next Year EPS Consensus Estimate: $-2.58 EPS

Dividends

Dividend History for Sienna Biopharmaceuticals (NASDAQ:SNNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sienna Biopharmaceuticals (NASDAQ SNNA)

Institutional Ownership Percentage: 23.33%
Insider Trades by Quarter for Sienna Biopharmaceuticals (NASDAQ:SNNA)
Insider Trades by Quarter for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Insider Trades by Quarter for Sienna Biopharmaceuticals (NASDAQ SNNA)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/18/2017Dennis M FentonDirectorBuy1,250$22.96$28,700.00View SEC Filing  
8/1/2017Keith R LeonardDirectorBuy16,700$15.00$250,500.00View SEC Filing  
8/1/2017Paul F LizzulInsiderBuy10,000$15.00$150,000.00View SEC Filing  
8/1/2017Richard D PetersonCFOBuy7,000$15.00$105,000.00View SEC Filing  
8/1/2017Timothy K AndrewsGeneral CounselBuy15,000$15.00$225,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sienna Biopharmaceuticals (NASDAQ SNNA)

Source:
DateHeadline
Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial ResultsSienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 1:45 PM
Sienna Biopharmaceuticals (SNNA) Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120Sienna Biopharmaceuticals (SNNA) Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
www.streetinsider.com - October 25 at 10:53 AM
Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
finance.yahoo.com - October 24 at 10:12 AM
SIENNA BIOPHARM (SNNA) Director Dennis M. Fenton Purchases 1,250 SharesSIENNA BIOPHARM (SNNA) Director Dennis M. Fenton Purchases 1,250 Shares
www.americanbankingnews.com - September 19 at 4:28 PM
SIENNA BIOPHARM (SNNA) Releases Quarterly  Earnings Results, Misses Expectations By $5.82 EPSSIENNA BIOPHARM (SNNA) Releases Quarterly Earnings Results, Misses Expectations By $5.82 EPS
www.americanbankingnews.com - September 8 at 9:29 AM
Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial ResultsSienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results
finance.yahoo.com - September 7 at 9:14 AM
Sienna Biopharms (SNNA) Quiet Period Will End  on September 5thSienna Biopharm's (SNNA) Quiet Period Will End on September 5th
www.americanbankingnews.com - September 2 at 1:22 AM
Sienna Biopharm (SNNA) Coverage Initiated at Cowen and CompanySienna Biopharm (SNNA) Coverage Initiated at Cowen and Company
www.americanbankingnews.com - August 21 at 8:52 AM
Sienna Biopharm (SNNA) Receives New Coverage from Analysts at J P Morgan Chase & CoSienna Biopharm (SNNA) Receives New Coverage from Analysts at J P Morgan Chase & Co
www.americanbankingnews.com - August 21 at 8:36 AM
Sienna Biopharm (SNNA) Now Covered by Analysts at BMO Capital MarketsSienna Biopharm (SNNA) Now Covered by Analysts at BMO Capital Markets
www.americanbankingnews.com - August 21 at 8:08 AM
Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesSienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - August 2 at 3:26 PM
Sienna Biopharmaceuticals Inc (SNNA) General Counsel Buys $225,000.00 in StockSienna Biopharmaceuticals Inc (SNNA) General Counsel Buys $225,000.00 in Stock
www.americanbankingnews.com - August 1 at 10:14 PM
Paul F. Lizzul Buys 10,000 Shares of Sienna Biopharmaceuticals Inc (SNNA) StockPaul F. Lizzul Buys 10,000 Shares of Sienna Biopharmaceuticals Inc (SNNA) Stock
www.americanbankingnews.com - August 1 at 7:50 PM
Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) CFO Acquires $105,000.00 in StockSienna Biopharmaceuticals Inc (NASDAQ:SNNA) CFO Acquires $105,000.00 in Stock
www.americanbankingnews.com - August 1 at 7:50 PM
Sienna Biopharmaceuticals Inc (SNNA) Director Keith R. Leonard Acquires 16,700 SharesSienna Biopharmaceuticals Inc (SNNA) Director Keith R. Leonard Acquires 16,700 Shares
www.americanbankingnews.com - August 1 at 7:48 PM
Sienna Biopharmaceuticals Prices IPO at $14.00-$16.00 Per Share (NASDAQ:SNNA)Sienna Biopharmaceuticals Prices IPO at $14.00-$16.00 Per Share (NASDAQ:SNNA)
www.americanbankingnews.com - July 19 at 10:58 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Sienna Biopharmaceuticals (NASDAQ SNNA) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.